Application of DNA Replicons in Gene Therapy and Vaccine Development

Lundström, Kenneth

doi:10.3390/pharmaceutics15030947

Cited by 4 publications

(2 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One approach involves the incorporation of genetic material encoding the epitope into host cells. By introducing this genetic material, the host cells gain the ability to produce the epitope themselves, consequently eliciting an immune response against the pathogen [ 61 , 62 , 63 ]. This strategy offers several advantages.…”

Section: Resultsmentioning

confidence: 99%

Epitopes and Mimotopes Identification Using Phage Display for Vaccine Development against Infectious Pathogens

Palma¹

2023

Vaccines

View full text Add to dashboard Cite

Traditional vaccines use inactivated or weakened forms of pathogens which could have side effects and inadequate immune responses. To overcome these challenges, phage display has emerged as a valuable tool for identifying specific epitopes that could be used in vaccines. This review emphasizes the direct connection between epitope identification and vaccine development, filling a crucial gap in the field. This technique allows vaccines to be engineered to effectively stimulate the immune system by presenting carefully selected epitopes. Phage display involves screening libraries of random peptides or gene/genome fragments using serum samples from infected, convalescent, or vaccinated individuals. This method has been used to identify epitopes from various pathogens including SARS-CoV-2, Mycobacterium tuberculosis, hepatitis viruses, H5N1, HIV-1, Human T-lymphotropic virus 1, Plasmodium falciparum, Trypanosoma cruzi, and Dirofilaria repens. Bacteriophages offer advantages such as being immunogenic carriers, low production costs, and customization options, making them a promising alternative to traditional vaccines. The purpose of this study has been to highlight an approach that encompasses the entire process from epitope identification to vaccine production using a single technique, without requiring additional manipulation. Unlike conventional methods, phage display demonstrates exceptional efficiency and speed, which could provide significant advantages in critical scenarios such as pandemics.

show abstract

Section: Resultsmentioning

confidence: 99%

Epitopes and Mimotopes Identification Using Phage Display for Vaccine Development against Infectious Pathogens

Palma¹

2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Similar to viral vectors, they are able to induce high levels of transgene expression and apoptosis in the transfected cell. Non-viral vectors based on alphaviruses could be used in the form of RNA directly or as DNA, in which the self-amplifying RNA is cloned under the control of a eukaryotic promoter allowing its transcription in the target cell [ 154 , 155 ]. We have previously demonstrated the remarkable antitumor potential of these strategies by delivering SFV RNA and DNA vectors expressing IL-12 or an anti-PD-1 nanobody, respectively, by electroporation in MC38 subcutaneous tumors [ 136 , 156 ].…”

Section: Viral Vectors To Deliver Immunomodulatory Antibodiesmentioning

confidence: 99%

Local Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors

Silva-Pilipich

Covo-Vergara

Smerdou

2023

Cancers

View full text Add to dashboard Cite

Cancer therapy has experienced a breakthrough with the use of immune checkpoint inhibitors (ICIs) based on monoclonal antibodies (mAbs), which are able to unleash immune responses against tumors refractory to other therapies. Despite the great advancement that ICIs represent, most patients with gastrointestinal tumors have not benefited from this therapy. In addition, ICIs often induce adverse effects that are related to their systemic use. Local administration of ICIs in tumors could concentrate their effect in the malignant tissue and provide a higher safety profile. A new and attractive approach for local delivery of ICIs is the use of gene therapy vectors to express these blocking antibodies in tumor cells. Several vectors have been evaluated in preclinical models of gastrointestinal tumors to express ICIs against PD-1, PD-L1, and CTLA-4, among other immune checkpoints, with promising results. Vectors used in these settings include oncolytic viruses, self-replicating RNA vectors, and non-replicative viral and non-viral vectors. The use of viral vectors, especially when they have replication capacity, provides an additional adjuvant effect that has been shown to enhance antitumor responses. This review covers the most recent studies involving the use of gene therapy vectors to deliver ICIs to gastrointestinal tumors.

show abstract

Induction of translation-suppressive G3BP1+ stress granules and interferon-signaling cGAS condensates by transfected plasmid DNA

Majerciak,

Zheng

2024

hLife

View full text Add to dashboard Cite

Application of DNA Replicons in Gene Therapy and Vaccine Development

Cited by 4 publications

References 74 publications

Epitopes and Mimotopes Identification Using Phage Display for Vaccine Development against Infectious Pathogens

Epitopes and Mimotopes Identification Using Phage Display for Vaccine Development against Infectious Pathogens

Local Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors

Induction of translation-suppressive G3BP1+ stress granules and interferon-signaling cGAS condensates by transfected plasmid DNA

Contact Info

Product

Resources

About